title: Antibody therapeutics in cancer.
abstract: In a relatively short period of time, monoclonal antibodies have entered the mainstream of cancer therapy. Their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as long-sought vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. With ever more promising results from the clinic, the future will likely see continued growth in the discovery and development of therapeutic antibodies and their derivatives.
authors.affiliation: Genentech, Incorporated, 1 DNA Way, South San Francisco, CA 94080, USA. marks@gene.com
authors.forename: Mark X
authors.initials: MX
authors.lastname: Sliwkowski
authors.forename: Ira
authors.initials: I
authors.lastname: Mellman
mesh_terms: D000911:Antibodies, Monoclonal / Q000145:classification* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004337:Drug Carriers; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D014677:Pharmaceutical Vehicles; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004337:Drug Carriers; D066246:ErbB Receptors; D014677:Pharmaceutical Vehicles; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human